Akone Sergi Herve, Ntie-Kang Fidele, Stuhldreier Fabian, Ewonkem Monique Bassomo, Noah Alexandre Mboene, Mouelle Simon Eitel Misse, Müller Rolf
Department of Chemistry, Faculty of Science, University of Douala, Douala, Cameroon.
Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Department of Pharmacy, Saarland University, Saarbrücken, Germany.
Front Pharmacol. 2020 Aug 13;11:992. doi: 10.3389/fphar.2020.00992. eCollection 2020.
Epigenetics refers to heritable changes in gene expression and chromatin structure without change in a DNA sequence. Several epigenetic modifications and respective regulators have been reported. These include DNA methylation, chromatin remodeling, histone post-translational modifications, and non-coding RNAs. Emerging evidence has revealed that epigenetic dysregulations are involved in a wide range of diseases including cancers. Therefore, the reversible nature of epigenetic modifications concerning activation or inhibition of enzymes involved could be promising targets and useful tools for the elucidation of cellular and biological phenomena. In this review, emphasis is laid on natural products that inhibit DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) making them promising candidates for the development of lead structures for anticancer-drugs targeting epigenetic modifications. However, most of the natural products targeting HDAC and/or DNMT lack isoform selectivity, which is important for determining their potential use as therapeutic agents. Nevertheless, the structures presented in this review offer the well-founded basis that screening and chemical modifications of natural products will in future provide not only leads to the identification of more specific inhibitors with fewer side effects, but also important features for the elucidation of HDAC and DNMT function with respect to cancer treatment.
表观遗传学是指在DNA序列不变的情况下,基因表达和染色质结构发生的可遗传变化。已有多种表观遗传修饰及其相应调节因子被报道。这些包括DNA甲基化、染色质重塑、组蛋白翻译后修饰以及非编码RNA。新出现的证据表明,表观遗传失调与包括癌症在内的多种疾病有关。因此,与所涉及酶的激活或抑制相关的表观遗传修饰的可逆性,可能成为阐明细胞和生物学现象的有前景的靶点和有用工具。在本综述中,重点关注抑制DNA甲基转移酶(DNMTs)和组蛋白去乙酰化酶(HDACs)的天然产物,这些天然产物有望成为开发针对表观遗传修饰的抗癌药物先导结构的候选物。然而,大多数靶向HDAC和/或DNMT的天然产物缺乏亚型选择性,而亚型选择性对于确定它们作为治疗剂的潜在用途很重要。尽管如此,本综述中呈现的结构提供了坚实的基础,即未来对天然产物的筛选和化学修饰不仅将有助于鉴定副作用更少的更具特异性的抑制剂,还将为阐明HDAC和DNMT在癌症治疗方面的功能提供重要特征。